Pylarify
Payments companies reported to CMS as associated with Pylarify. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Pylarify, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Pylarify
These are the largest totals companies reported as associated with Pylarify. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| April Teitelbaum | San Diego, CA | Medical Oncology | $743,198.98 |
| Gary Ulaner | Los Angeles, CA | Diagnostic Radiology | $372,295.54 |
| Edward Obedian | Oyster Bay, NY | Radiation Oncology | $341,474.12 |
| Steven Rowe | Dallas, TX | Diagnostic Radiology | $290,696.67 |
| Medhat Osman | St Louis, MO | Nuclear Medicine | $282,653.98 |
| Daniel Appelbaum | Chicago, IL | Nuclear Radiology | $246,826.37 |
| Tony Abraham | Port Jefferson Station, NY | Nuclear Radiology | $235,989.96 |
| Giuseppe Esposito | Washington, DC | Nuclear Medicine | $199,338.36 |
| Hossein Jadvar | Los Angeles, CA | Nuclear Medicine | $169,402.52 |
| Glen Mcwilliams | Bronx, NY | Urology | $115,017.59 |
Prescribed Pylarify?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.